Search

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Lymphoid malignancies dissected in Warsaw

The EHA–PTHiT Tutorial on Lymphoid Malignancies was held on March 17-18, 2017 in Warsaw, Poland. 96% of meeting attendees were satisfied with the tutorial saying that their expectations are met.

Read more

Celebrating the International Day of Women & Girls in Science

On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

YoungEHA Mentorship Mixer at EHA2024

Hosted by the YoungEHA Committee, the Mentorship Mixer is a pilot event for a potential EHA mentorship program.

Read more

Enabling the spread of good research – a day in the life of an Editor-in-Chief

Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.

Read more

New data exchange platform on rare diseases

The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.

Read more

Rebuilding the future for hematology in Ukraine today

The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.

Read more